Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site. # Capsida Biotherapeutics Enginerering the gene therapies of tomorrow ## Sitemaps - [XML Sitemap](https://capsida.com/sitemap.xml): Contains all public & indexable URLs for this website. ## Posts - [Capsida to Present Preclinical Data of New Next-Generation, High-Performing Ocular Capsids at ASGCT Annual Meeting](https://capsida.com/capsida-to-present-preclinical-data-of-new-next-generation-high-performing-ocular-capsids-at-asgct-annual-meeting/) - Provides corporate update including appointment of gene therapy expert Romuald Corbau, Ph.D., as Chief Scientific Officer and an update on the CNS programs THOUSAND OAKS, Calif., May 12, 2026 — Capsida Biotherapeutics, (“Capsida”) a next-generation genetic medicines company, today provided corporate and pipeline updates related to its ocular and central nervous system (CNS) programs. Capsida’s Next - [CAP-002 Program Update: A Letter to the STXBP1 Community](https://capsida.com/stx-community-letter-5-9-2026/) - We wanted to provide an update following our January 8, 2026 letter. - [An Important Update Regarding Our CAP-002 Program: A Letter to the STXBP1 Community](https://capsida.com/an-important-update-regarding-our-cap-002-program-a-letter-to-the-stxbp1-community/) - To the STXBP1 Community: The team at Capsida is very aware that the STXBP1 community is anxious to learn more about the unexpected and devastating loss of the first patient dosed in our SYNRGY trial for STXBP1 Related DEE. Although our investigation is not complete, we wanted to provide you with an update about our - [A Letter to the STXBP1 Community](https://capsida.com/a-letter-to-the-stxbp1-community/) - To the STXBP1 Community: It is with heavy hearts that we share that the first patient to participate in our SYNRGY trial for STXBP1-Related Disorders passed away. We wish to express our deepest condolences to the patient’s family and know that the entire community is grieving this loss. We understand this devastating news will raise questions - [Capsida Receives FDA IND Clearance for Its IV-Administered Gene Therapy for Parkinson’s Disease Associated with GBA Mutations](https://capsida.com/capsida-receives-fda-ind-clearance-for-its-iv-administered-gene-therapy-for-parkinsons-disease-associated-with-gba-mutations/) - Capsida is initiating the Phase 1/2 study for CAP-003, with the first patient expected to be dosed in the third quarter of this year THOUSAND OAKS, Calif., June 11, 2025 — Capsida Biotherapeutics (“Capsida”) today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAP-003, its potential best-in-class - [Capsida Receives FDA Fast Track Designation for Its Potential First-in-Class IV-Administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy](https://capsida.com/capsida-receives-fda-fast-track-designation-for-its-potential-first-in-class-iv-administered-gene-therapy-for-stxbp1-developmental-and-epileptic-encephalopathy/) - Capsida previously received FDA Orphan Drug Designation and IND clearance to initiate the SYNRGY Phase 1/2a clinical trial for CAP-002 THOUSAND OAKS, Calif., May 29, 2025 — Capsida Biotherapeutics (“Capsida”) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its CAP-002 program. CAP-002 is the company’s investigational IV-administered gene therapy - [Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance of Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy](https://capsida.com/capsida-presents-new-glp-toxicology-data-supporting-recent-fda-ind-clearance-of-its-first-in-class-iv-administered-gene-therapy-for-stxbp1-developmental-and-epileptic-encephalopathy/) - Data show CAP-002 has potential to safely correct seizures, developmental disabilities, and motor abnormalities after single IV infusion Oral presentation today at ASGCT 2025 annual meeting THOUSAND OAKS, Calif., May 14, 2025 — Capsida Biotherapeutics (“Capsida”) today announced the presentation of new non-human primate (NHP) GLP toxicology data for CAP-002, its wholly owned first-in-class, intravenously - [Capsida Receives FDA IND Clearance for Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy](https://capsida.com/capsida-receives-fda-ind-clearance-for-its-first-in-class-iv-administered-gene-therapy-for-stxbp1-developmental-and-epileptic-encephalopathy/) - CAP-002 is the first engineered IV-delivered gene therapy that crosses the blood-brain-barrier and detargets the liver and dorsal root ganglia to enter the clinic THOUSAND OAKS, Calif., May 12, 2025 — Capsida Biotherapeutics (“Capsida”) today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAP-002, its wholly - [Capsida to Present Progress Updates at the ASGCT Annual Meeting, Including NHP GLP Toxicology Study Results for its Potential First-in-Class STXBP1 Developmental and Epileptic Encephalopathy Program (CAP-002 STXBP1-DEE)](https://capsida.com/capsida-to-present-progress-updates-at-the-asgct-annual-meeting-including-nhp-glp-toxicology-study-results-for-its-potential-first-in-class-stxbp1-developmental-and-epileptic-encephalopathy-program/) - Capsida will also present data from its potential best-in-class programs for Parkinson’s disease associated with GBA mutations (CAP-003 PD-GBA) and Friedreich’s ataxia (CAP-004), as well as capsid engineering and manufacturing Both CAP-002 STXBP1-DEE and CAP-003 PD-GBA are on track to enter clinical development this quarter THOUSAND OAKS, Calif., April 28, 2025 — Capsida Biotherapeutics (“Capsida”) - [Capsida Presents New Data from GLP Toxicology Study in NHPs Demonstrating Potential Best-in-Class Profile of CAP-003 in Patients with Parkinson’s Disease Associated with GBA Mutations (PD-GBA)](https://capsida.com/capsida-presents-new-data-from-glp-toxicology-study-in-nhps-demonstrating-potential-best-in-class-profile-of-cap-003-in-patients-with-parkinsons-disease-associated-with-gba-mutations-pd-gba/) - GCase elevations meaningfully exceeding efficacy threshold, well-tolerated safety profile, and IV-administration support advancing CAP-003 into clinical development in 1H25. THOUSAND OAKS, Calif., April 3, 2025 – Capsida Biotherapeutics (“Capsida”) today announced new data from the three-month cohort of a GLP toxicology study in non-human primates (NHPs) with CAP-003, its intravenously (IV) delivered gene therapy for - [Capsida Announces AbbVie Opt-in for First Genetic Medicine Program from Neurodegenerative Disease Collaboration](https://capsida.com/capsida-announces-abbvie-opt-in-for-first-genetic-medicine-program-from-neurodegenerative-disease-collaboration/) - Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties THOUSAND OAKS, Calif., January 7, 2025 – Capsida Biotherapeutics (“Capsida”) today announced that AbbVie has exercised an option for the first neurodegenerative disease program under their ongoing collaboration. Capsida will receive a $40 million license payment and is eligible - [Capsida Biotherapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference](https://capsida.com/capsida-biotherapeutics-to-present-at-43rd-annual-j-p-morgan-healthcare-conference/) - THOUSAND OAKS, Calif., December 19, 2024 — Capsida Biotherapeutics (“Capsida”), leader in next-generation IV-administered central nervous system (CNS) gene therapies, today announced it will present at the 43rd Annual J.P. Morgan Healthcare Conference. Chief Executive Officer Peter Anastasiou will provide an update on the company’s wholly owned CNS pipeline on Thursday, January 16, 2025 at - [New Preclinical Data Demonstrate Potential of Capsida’s IV Gene Therapy for STXBP1-DEE to Correct all Disease Manifestations](https://capsida.com/new-preclinical-data-demonstrate-potential-of-capsidas-iv-gene-therapy/) - Data to be featured as oral and poster presentations at American Epilepsy Society 2024 Annual Meeting THOUSAND OAKS, Calif., December 6, 2024 — Capsida Biotherapeutics (“Capsida”) today announced new preclinical data on CAP-002, its first-in-class IV-administered next-generation gene therapy candidate for developmental and epileptic encephalopathy (DEE) due to syntaxin-binding protein 1 (STXBP1) mutations. The new data - [Capsida Biotherapeutics to Present at 7th Annual Evercore HealthCONx Conference](https://capsida.com/capsida-biotherapeutics-to-present-at-7th-annual-evercore-healthconx-conference/) - THOUSAND OAKS, Calif., November 25, 2024 — Capsida Biotherapeutics (“Capsida”), a leading fully integrated next-generation gene therapy company developing treatments for rare and common diseases across all ages, today announced that the company will present at the 7th Annual Evercore HealthCONx Conference being held December 3-5, 2024 in Coral Gables, FL. Management will highlight progress - [Capsida Biotherapeutics to Present New Preclinical Data for Potential Best-in-Class Friedreich’s Ataxia Next-Generation Gene Therapy](https://capsida.com/capsida-biotherapeutics-to-present-new-preclinical-data-for-potential-best-in-class-friedreichs-ataxia-next-generation-gene-therapy/) - NHP data demonstrate potential for CAP-004 to treat CNS, cardiac, and sensory manifestations of Friedreich’s ataxia - [FDA Grants Orphan Drug Designation to Capsida Biotherapeutics for Potential Treatment of STXBP1 Developmental and Epileptic Encephalopathy](https://capsida.com/fda-grants-orphan-drug-designation-to-capsida-biotherapeutics-for-potential-treatment-of-stxbp1-developmental-and-epileptic-encephalopathy/) - Wholly owned first-in-class program anticipated to enter clinical trials in first half of 2025 THOUSAND OAKS, Calif., October 30, 2024 – Capsida Biotherapeutics (“Capsida”) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Capsida for CAP-002. CAP-002 is the company’s lead investigational gene therapy for the treatment of - [New Data Demonstrate Substantial Therapeutic Potential of Capsida’s IV Gene Therapy for Parkinson’s Disease Associated with GBA Mutations](https://capsida.com/new-data-demonstrate-substantial-therapeutic-potential-of-capsidas-iv-gene-therapy-for-parkinsons-disease-associated-with-gba-mutations/) - CAP-003 achieved best-in-class GCase increases in NHPs exceeding levels needed for normalizing activity in patients Brainwide RNA expression greater than 200-fold higher than AAV9, with significant detargeting of liver and DRGs with proprietary engineered capsid Company on track to file IND in first half of 2025 THOUSAND OAKS, Calif., October 7, 2024 — Capsida Biotherapeutics - [Capsida Biotherapeutics to Participate in Upcoming Investor and Industry Conferences Highlighting Progress With its Wholly Owned Programs in IND-enabling Studies](https://capsida.com/capsida-to-participate-in-upcoming-investor-and-industry-conferences/) - Presentations to include data from IV-administered programs in genetic epilepsy due to STXBP1 mutations and Parkinson’s disease with GBA mutations THOUSAND OAKS, Calif., September 4, 2024 – Capsida Biotherapeutics (“Capsida”), a leading fully integrated targeted gene therapy company, developing treatments for rare and common diseases across all ages, today announced that the company will participate - [Capsida Biotherapeutics to Present Preclinical Data for Parkinson’s Disease Associated with GBA Mutations Showing High Levels of GCase Enzyme Supplementation Following IV Administration](https://capsida.com/capsida-biotherapeutics-to-present-preclinical-data-for-parkinsons-disease/) - Next-generation gene therapy demonstrates best-in-class potential with majority of neurons transduced in substantia nigra and high levels of GCase supplementation after single IV infusion Broad GCase elevation achieved in NHPs, while significantly detargeting the liver compared with AAV9, with no clinical pathology, immunogenicity, or histopathology findings, including in DRGs Wholly owned program on track for - [Capsida Biotherapeutics Presents New Preclinical Evidence Indicating Novel First-in-Class IV-Administered Gene Therapy Effectively Treats Genetic Epilepsy Due to STXBP1 Mutations](https://capsida.com/capsida-biotherapeutics-presents-new-preclinical-evidence/) - Dose-dependent rescue of neurological phenotypes, including epileptic seizures, motor deficits, and cognitive impairments, with long-lasting effects in adult mice Capsida poster will also show new data with its next-generation gene therapy showing significant brain-wide expression of STXBP1 protein and liver detargeting after a single IV infusion Wholly owned program is first in class and currently - [Capsida Biotherapeutics to Present New Data on its Wholly Owned Gene Therapy Programs in Genetic Epilepsy and Parkinson’s Disease at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)](https://capsida.com/capsida-biotherapeutics-to-present-new-data-on-its-wholly-owned-gene-therapy-programs/) - Company unveils Parkinson’s disease associated with GBA mutations (PD-GBA) program; two oral presentations feature new data from Capsida’s wholly owned programs in PD-GBA and genetic epilepsy due to STXBP1 mutations; both programs in IND-enabling studies to support initiation of clinical trials first half of 2025 - [Capsida Biotherapeutics Announces Promotion of Rob Murphy to Chief Manufacturing and Quality Officer](https://capsida.com/promotion-of-rob-murphy-to-chief-manufacturing-and-quality-officer/) - Promotion reinforces commitment to advancing our wholly owned gene therapy pipeline and strength of in-house manufacturing capabilities THOUSAND OAKS, Calif., March 12, 2024— Capsida Biotherapeutics (“Capsida”), a leading fully integrated targeted gene therapy company, developing treatments for rare and common diseases across all ages, today announced the promotion of Rob Murphy to Chief Manufacturing and - [Capsida Biotherapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference](https://capsida.com/capsida-biotherapeutics-to-present-at-evercore-isi-2024-emerging-biotech-conference/) - THOUSAND OAKS, Calif., February 21, 2024 -- Capsida Biotherapeutics (“Capsida”) today announced that Peter Anastasiou, Chief Executive Officer, will present a corporate update at the Evercore ISI 2024 Emerging Biotech Conference which is being held virtually February 28-29, 2024. Mr. Anastasiou’s presentation will take place on Thursday, February 29, 2024, at 2:15PM ET. The Capsida - [Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx’s Next-Generation Gene Therapies](https://capsida.com/capsida-biotherapeutics-enters-strategic-collaboration-with-kate-therapeutics-to-manufacture-katetxs-next-generation-gene-therapies/) - Strategic partnership leverages Capsida’s next-generation manufacturing capabilities to enable development of KateTx’s gene therapy medicines for muscle and heart diseases THOUSAND OAKS, Calif. and SAN DIEGO – October 3, 2023 – Capsida Biotherapeutics Inc. (“Capsida”) and Kate Therapeutics (“KateTx”) today announced a strategic partnership to leverage Capsida’s expertise and adeno-associated virus (AAV) manufacturing capabilities to - [Capsida Biotherapeutics to Present at Jefferies Cell & Genetic Medicine Summit and the 2023 Cell & Gene Meeting on the Mesa](https://capsida.com/capsida-biotherapeutics-to-present-at-jefferies-cell-genetic-medicine-summit-and-the-2023-cell-gene-meeting-on-the-mesa/) - THOUSAND OAKS, Calif., September 20, 2023 -- Capsida Biotherapeutics (“Capsida”) today announced that Peter Anastasiou, Chief Executive Officer, will present a corporate update at the following upcoming investor and industry conferences: Jefferies Cell & Genetic Medicine Summit on Wednesday, September 27, 2023 at 9:30 AM ET. The meeting is being held September 26-27, 2023 in - [Capsida Biotherapeutics Announces Publication in Nature Nanotechnology Identifying Novel Capsid With Significantly Increased Brain Transduction](https://capsida.com/capsida-biotherapeutics-announces-publication-in-nature-nanotechnology-identifying-novel-capsid-with-significantly-increased-brain-transduction/) - Foundational research by Capsida and Caltech demonstrates ability to engineer AAVs with improved efficacy over AAV9 to transduce brain in non-human primates Peer-reviewed publication highlights early work leading to Capsida’s recent breakthrough data presented at ASGCT THOUSAND OAKS, Calif., July 11, 2023 -- Capsida Biotherapeutics (“Capsida”) today announced research published in Nature Nanotechnology describing an - [Capsida Biotherapeutics to Present New Preclinical Data on Potential of Systemically Delivered Next-Generation AAV Therapeutics for Treatment of Genetic Epilepsy](https://capsida.com/capsida-biotherapeutics-to-present-new-preclinical-data-on-potential-of-systemically-delivered-next-generation-aav-therapeutics-for-treatment-of-genetic-epilepsy/) - Preclinical data show IV administration of a next-generation gene therapy produced dose-dependent replacement of syntaxin-binding protein 1 (STXBP1) throughout the brain, with efficacy predictive of clinical relevance lasting at least 12 months post therapeutic intervention. - [Capsida Biotherapeutics to Present New Data Showing Increased Capsid Expression in CNS at American Society of Gene & Cell Therapy 26th Annual Meeting](https://capsida.com/capsida-biotherapeutics-to-present-new-data-showing-increased-capsid-expression-in-cns-at-american-society-of-gene-cell-therapy-26th-annual-meeting/) - Preliminary data show next-generation engineered capsids in non-human primates delivered systemically resulted in widespread transduction in up to 68% of neurons across multiple brain regions Data to be showcased during industry-sponsored symposium about unlocking the potential of gene therapy with panel featuring academic and industry luminaries in gene therapy Poster presentations highlight optimization of process - [Capsida Biotherapeutics Appoints Susan Catalano, Ph.D. as Chief Scientific Officer](https://capsida.com/capsida-biotherapeutics-appoints-susan-catalano-ph-d-as-chief-scientific-officer/) - Industry veteran added to complement co-founders Nicholas Flytzanis, Ph.D. and Nick Goeden, Ph.D., to build on Company’s excellence in next-generation gene therapy science and bolster efforts to advance novel platform to patients Flytzanis will continue to lead research and platform innovation as Chief Research and Innovation Officer and Goeden will continue to lead technology development - [AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need](https://capsida.com/abbvie-and-capsida-biotherapeutics-expand-strategic-collaboration-to-develop-targeted-genetic-medicines-for-eye-diseases-with-high-unmet-need/) - AbbVie (NYSE: ABBV) and Capsida Biotherapeutics Inc. ("Capsida") today announced an expanded strategic collaboration to develop genetic medicines for eye diseases with high unmet need. AbbVie's extensive capabilities will be paired with Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability to identify and advance three programs. The collaboration builds upon the neurodegenerative disease partnership announced in 2021. - [Capsida Biotherapeutics Presents Data Demonstrating Unique Industry-Leading Technology and Capabilities With Potential to Treat Both Rare and Common Diseases at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)](https://capsida.com/capsida-biotherapeutics-presents-data-demonstrating-unique-industry-leading-technology-and-capabilities-with-potential-to-treat-both-rare-and-common-diseases-at-the-annual-meeting-of-the-american-soci/) - Platform utilizes combinatorial engineering and automation to screen in high-throughput, generating capsids greatly improved over AAV9 in CNS efficiency and specificity. Process development and manufacturing data validate in-house capability to produce highly productive and scalable processes up to 200L. - [Capsida Biotherapeutics Announces Appointment of Julie Hakim as Chief Financial Officer](https://capsida.com/capsida-biotherapeutics-announces-appointment-of-julie-hakim-as-chief-financial-officer/) - Hakim brings more than 25 years’ experience leading finance and exponential growth at both large and small companies THOUSAND OAKS, Calif., January 18, 2023 — Capsida Biotherapeutics Inc. (“Capsida”) today announced the appointment of Julie Hakim to the role of chief financial officer (CFO). Ms. Hakim will join Capsida’s leadership team and be responsible for directing - [Capsida Biotherapeutics Announces Strategic Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Develop Non-Invasive Gene Therapies for CNS Diseases](https://capsida.com/strategic-collaboration-with-prevail/) - THOUSAND OAKS, Calif. January 4, 2023 – Capsida Biotherapeutics Inc. (“Capsida”) today announced a multi-year strategic collaboration with Prevail Therapeutics (“Prevail”), a wholly owned subsidiary of Eli Lilly and Company (“Lilly”), to develop transformative genetic medicines for serious diseases. As part of the collaboration, Prevail will leverage Capsida’s novel adeno-associated virus (AAV) engineering platform to - [Capsida Appoints Swati Tole, M.D., as Chief Medical Officer](https://capsida.com/capsida-appoints-swati-tole-m-d-as-chief-medical-officer/) - Capsida Biotherapeutics Inc., a biotechnology company, today announced the appointment of Swati Tole, M.D., as the Company’s first chief medical officer. - [Capsida Biotherapeutics Presents New Data Validating Potential of Its Targeted, Non-invasive Gene Therapy Platform at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)](https://capsida.com/capsida-biotherapeutics-presents-new-data-validating-potential-of-its-targeted-non-invasive-gene-therapy-platform-at-the-annual-meeting-of-the-american-society-of-gene-cell-therapy-asgct/) - Preclinical results demonstrate proof-of-concept of early generation AAV-engineered capsid in MPSII pilot program. Data from capsid engineering platform show greater than 100-fold improvement over AAV9 across both infants and juveniles. Top capsid variants show broad protein expression across the primate CNS. - [Capsida Co-Founders Named to Endpoints’ Top 20 Scientists Under 40](https://capsida.com/capsida-co-founders-named-to-endpoints-top-20-scientists-under-40/) - Dr. Nick Goeden and Dr. Nick Flytzanis – “the Nicks,” as many of their colleagues call them – have a lot in common. They’re both co-founders and leaders at Capsida Biotherapeutics. They’re both 35 years old. And, this month, they were both named to the 2022 Endpoints “20 Under 40” list. This annual honor, selected - [Capsida Biotherapeutics Announces Appointment of Rayne Waller to Chief Operating Officer](https://capsida.com/capsida-biotherapeutics-announces-appointment-of-rayne-waller-to-chief-operating-officer/) - Company creates chief operating officer role and appoints veteran manufacturing and supply-chain executive Rayne Waller to help Capsida capitalize on its platform gene therapy technology, bringing treatments to patients with debilitating and life-threatening genetic disorders Mr. Waller will retain responsibility for manufacturing in addition to other operational functions Company's proprietary technology allows for targeted non-invasive - [PharmaVoice profiles Capsida CEO Peter Anastasiou](https://capsida.com/pharmavoice-profiles-capsida-ceo-peter-anastasiou/) - Capsida Biotherapeutics CEO Peter Anastasiou aims to bring AAV therapy to reality Anastasiou’s key to leadership stands at the intersection of what’s right for patients and business. As the CEO of Capsida Biotherapeutics, Peter Anastasiou is optimistic — no, let's make that excited — that the company’s novel and proprietary next-generation adeno-associated virus (AAV) platform - [Capsida Biotherapeutics Announces Publication in Nature Neuroscience From Caltech Demonstrating Robust, Non-invasive IV Gene Delivery Targeted to the Brain While Avoiding Liver](https://capsida.com/capsida-biotherapeutics-announces-publication-in-nature-neuroscience-from-caltech-demonstrating-robust-non-invasive-iv-gene-delivery-targeted-to-the-brain-while-avoiding-liver/) - THOUSAND OAKS, Calif., December 9, 2021 -- Capsida Biotherapeutics, Inc., an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening genetic disorders, today announced research published in Nature Neuroscience that demonstrated the ability to engineer and select novel capsid variants, with improved enrichment in - [Capsida Biotherapeutics Poised to Capitalize on Industry-leading Gene Therapy Technology With New CEO, CSO, and CTO](https://capsida.com/capsida-biotherapeutics-poised-to-capitalize-on-industry-leading-gene-therapy-technology-with-new-ceo-cso-and-cto/) - Longtime industry executive Peter Anastasiou appointed Chief Executive Officer Capsida co-founders Nicholas Flytzanis, Ph.D., promoted to Chief Scientific Officer and Nick Goeden, Ph.D., promoted to Chief Technology Officer Company’s proprietary technology allows for targeted non-invasive gene therapy for the brain and body, while limiting collateral impact on non-targeted areas THOUSAND OAKS, Calif., December 7, 2021 - [Capsida Technology and Clinical Leadership to Present at Gene Therapy for Neurological Disorders Conference](https://capsida.com/capsida-technology-and-clinical-leadership-to-present-at-gene-therapy-for-neurological-disorders-conference/) - Capsida Biotherapeutics Inc., a fully integrated biotechnology company creating a new class of targeted adeno-associated virus (AAV) gene therapies for patients with debilitating and life-threatening genetic disorders, is pleased to announce that co-founder and vice president of Technology Nick Goeden, PhD, and Swati Tole, MD MS, will speak at the Gene Therapy for Neurological Disorders - [Capsida Biotherapeutics Unveils Next-Generation Gene Therapy Manufacturing](https://capsida.com/capsida-biotherapeutics-unveils-next-generation-gene-therapy-manufacturing/) - New 15,000 square-foot facility in Thousand Oaks will enable industry leading end-to-end gene therapy manufacturing capability THOUSAND OAKS, Calif., July 22, 2021 – Capsida Biotherapeutics Inc., a fully integrated biotechnology company creating a new class of targeted adeno-associated virus (AAV) gene therapies for patients with debilitating and life-threatening genetic disorders, today announced the opening of - [CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia](https://capsida.com/crispr-capsida-collaboration/) - Collaboration leverages expertise and capabilities of both companies towards developing life-changing treatments for severe neurological diseases ZUG, Switzerland, CAMBRIDGE, Mass., and THOUSAND OAKS, Calif. – June 15, 2021 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and Capsida Biotherapeutics Inc., a biotechnology company dedicated to developing - [Capsida Biotherapeutics Debuts with $140 Million of Capital](https://capsida.com/capsida-biotherapeutics-debut/) - Versant Ventures and Westlake Village BioPartners today announced the emergence from stealth mode of Capsida Biotherapeutics Inc., a biotechnology company using an adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases. ## Pages - [Home](https://capsida.com/) - Capsida Biotherapeutics is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening disorders. - [Nicholas Flytzanis, Ph.D.](https://capsida.com/team/nicholas-flytzanis/) - Nicholas Flytzanis co-founded Capsida Biotherapeutics and serves as Chief Scientific Officer. Prior to co-founding Capsida, Dr. Flytzanis served as scientific director of the CLOVER research center at the California Institute of Technology (Caltech), leading an interdisciplinary team to develop and disseminate emerging technologies focused on the cross-section of neurological research and gene therapy. - [About](https://capsida.com/about/) - Capsida Biotherapeutics is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening disorders. - [Science & Innovation](https://capsida.com/science-innovation/) - Capsid Engineering, Cargo Optimization, Translational Biology, Process Development and Manufacturing, and Clinical Development All Under One Roof. Capsida Biotherapeutics has designed one of the industry’s only fully integrated, end-to-end gene therapy solutions. - [Szilárd Kiss, MD, FASRS](https://capsida.com/team/szilard-kiss/) - Szilárd Kiss, MD, FASRS Szilárd Kiss, MD, FASRS, is an internationally recognized retina specialist, surgeon-scientist, and physician-executive with deep expertise in ocular gene therapy, translational medicine, clinical development, and regulatory strategy. He serves as the Bob and Dolores Hope–Robert M. Ellsworth, M.D. Distinguished Professor in Ophthalmology, Professor of Ophthalmology in Genetic Medicine, Chief of the - [Mina Kim](https://capsida.com/team/mina-kim/) - Mina KimExecutive Chair Mina Kim serves as Capsida’s Executive Chair of the board of directors. She has more than 20 years of operational and leadership experience. Ms. Kim previously served as Acelyrin’s Chief Executive Officer and Chief Legal and Administrative Officer. Prior to that, she served as Chief Legal Officer and Head of Corporate Development - [Amar Duvvur](https://capsida.com/team/amar-duvvur/) - Amar DuvvurChief Operating Officer & Chief Financial Officer Amar Duvvur serves as Capsida’s Chief Operating Officer & Chief Financial Officer. He has over 25 years of finance leadership experience across public and private companies spanning biotech, pharmaceuticals, medical devices, and diversified industrials. Mr. Duvvur has led various functions including FP&A, treasury, and operations finance. He - [Publications](https://capsida.com/publications/) - PUBLICATIONS CATCH UP WITH OUR LATEST PUBLICATIONS Poster presentation from the American Society for Gene & Cell Therapy Annual Meeting – May 2026 Identification of high-performing ocular AAV capsids through directed engineering across intravitreal and suprachoroidal delivery routes – Download PDF Oral presentation from GBA1 Meeting – June 2025 CAP-003: A Novel Investigational CNS-targeted Intravenous - [Romuald Corbau, Ph.D.](https://capsida.com/team/romuald-corbau/) - Romuald Corbau, Ph.D.Chief Scientific Officer Romuald Corbau, Ph.D., is Chief Scientific Officer at Capsida Biotherapeutics. Dr. Corbau has over 27 years of experience in gene therapy and drug discovery across startups and global organizations in the United States and Europe. Prior to Capsida, Dr. Corbau served as Chief Scientific Officer at Adverum Biotechnologies (acquired by - [Terms of Use](https://capsida.com/terms-of-use/) - OUR PIPELINE IS MAKING THE IMPOSSIBLE POSSIBLETERMS AND CONDITIONS OF USEEffective date: 8/1/2025 Last updated: 4/6/2026 Welcome to Capsida. Please read on to learn the rules and restrictions that govern your use of our website (the “Site”). If you have any questions, comments, or concerns regarding these terms or the Site, please contact us at: - [Community Updates](https://capsida.com/community-updates/) - COMPANY UPDATES May 11, 2026CAP-002 Program Update: A Letter to the STXBP1 Community January 8, 2026An Important Update Regarding Our CAP-002 Program: A Letter to the STXBP1 Community September 10, 2025A Letter to the STXBP1 Community - [Press Releases](https://capsida.com/press-releases/) - PRESS RELEASES CATCH UP WITH OUR LATEST PRESS RELEASES May 12, 2026Capsida to Present Preclinical Data of New Next-Generation, High-Performing Ocular Capsids at ASGCT Annual Meeting June 11, 2025Capsida Receives FDA IND Clearance for Its IV-Administered Gene Therapy for Parkinson’s Disease Associated with GBA Mutations May 29, 2025Capsida Receives FDA Fast Track Designation for Its - [Privacy Policy](https://capsida.com/privacy-policy/) - PRIVACY POLICYAt Capsida, we take your privacy seriously. Please read this Privacy Policy to learn how we treat your personal data. By using or accessing our Site in any manner, you acknowledge that you accept the practices and policies outlined below, and you hereby consent that we will collect, use and disclose your information as - [Contact](https://capsida.com/contact/) - We harness the power of our diverse backgrounds and thoughts to deliver on our purpose. We have a sense of collective responsibility and unity. - [Beth Seidenberg, M.D.](https://capsida.com/team/beth-seidenberg-m-d/) - Beth Seidenberg, M.D., is a longtime life sciences investor, applying her broad medical expertise to the venture capital world, where she assists entrepreneurs in translating their scientific breakthroughs into new medicines to help patients. - [Clare Ozawa, Ph.D.](https://capsida.com/team/clare-ozawa/) - Clare Ozawa brings extensive operations and big pharma experience to Capsida’s board. Currently a Managing Director at Versant Ventures, Dr. Ozawa previously held leadership roles at Inception Sciences, including as Chief Business Officer and Chief Operating Officer. - [Bethany Mancilla](https://capsida.com/team/bethany-mancilla/) - Bethany Mancilla is the Chief Business Officer at Capsida Biotherapeutics, a fully integrated gene therapy company developing next generation AAV engineered therapies. Bethany has over 25 years of biotechnology leadership experience in business development, corporate strategy and financing across small and large biopharmaceutical companies. Bethany began her career commercializing innovations and establishing start-up companies from - [Careers](https://capsida.com/careers/) - Seize the opportunity to be at the forefront of gene therapy. Capsida is a rapidly growing company based in the heart of the Greater Los Angeles biotech hub. We’re looking for passionate, dedicated colleagues to join us. - [Team](https://capsida.com/team/) - Built through a combination of in-house R&D and industry partnerships, our therapeutic approaches – including gene replacement and gene editing – are designed to bring therapies to patients with both monogenic and polygenic diseases. - [News](https://capsida.com/news-events/) - Through intravenous (IV) delivery of a single, engineered capsid, Capsida’s technology can target single or multiple organs simultaneously while limiting exposure to non-targeted organs. - [News and Events Future](https://capsida.com/news-and-events-future/) - NEWS & EVENTS CATCH UP WITH OUR LATEST NEWS May 12, 2026Capsida to Present Preclinical Data of New Next-Generation, High-Performing Ocular Capsids at ASGCT Annual MeetingProvides corporate update including appointment of gene therapy expert Romuald… May 11, 2026CAP-002 Program Update: A Letter to the STXBP1 Community May 2023 Optimization of a Versatile Downstream Process for - [Connect with Capsida at ASGCT](https://capsida.com/connect-with-capsida-at-asgct/) - Connect with Capsida at ASGCT Connect with Capsida at ASGCT May 16-20, 2023 Los Angeles, California Are you attending the American Society of Gene and Cell Therapy Annual Meeting in LA? If so, we’d love to connect with you. Please come by and say hi, and mark your calendar to attend any of these events. - [Page 404 Custom](https://capsida.com/page-404-custom/) - The page you are looking for was not found. - [Maintenance Mode](https://capsida.com/maintenance-mode/) - The website is in maintenance mode.Custom maintenance mode page. In an ideal world this website wouldn’t exist, a client would acknowledge the importance of having web copy before the design starts. Needless to say it’s very important, content is king and people are beginning to understand. STATUS PROGRESS 90% Back Homepage ## Portfolio - [Centered Gallery Full-Width](https://capsida.com/portfolio/centered-gallery-full-width/) - We are excited to launch our new company and product Ooooh. After being featured in too many magazines to mention and having created an online stir, we know that Ooooh is going to be big. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. We also hope to win Startup Fictional Business of the Year this Year. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. - [Sidebar Stack](https://capsida.com/portfolio/sidebar-stack/) - We are excited to launch our new company and product Ooooh. After being featured in too many magazines to mention and having created an online stir, we know that Ooooh is going to be big. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. - [Sidebar Slides Full-Width](https://capsida.com/portfolio/sidebar-slides-full-width/) - We are excited to launch our new company and product Ooooh. After being featured in too many magazines to mention and having created an online stir, we know that Ooooh is going to be big. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. We also hope to win Startup Fictional Business of the Year this Year. - [Centered Slides](https://capsida.com/portfolio/centered-slides/) - We are excited to launch our new company and product Ooooh. After being featured in too many magazines to mention and having created an online stir, we know that Ooooh is going to be big. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. We also hope to win Startup Fictional Business of the Year this Year. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. - [Sidebar Gallery Full-Width](https://capsida.com/portfolio/sidebar-gallery-full-width/) - We are excited to launch our new company and product Ooooh. After being featured in too many magazines to mention and having created an online stir, we know that Ooooh is going to be big. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. We also hope to win Startup Fictional Business of the Year this Year. - [Sidebar Dynamic Contents](https://capsida.com/portfolio/sidebar-dynamic-contents/) - Dynamic Contents play an essential role in creating layout templates. The Dynamic Contents features let you automatically insert content from WordPress in your designs. With the Dynamic Contents options, it's possible to create personalized and dynamic layouts by populating data from various sources. - [Centered Stack](https://capsida.com/portfolio/centered-stack/) - We are excited to launch our new company and product Ooooh. After being featured in too many magazines to mention and having created an online stir, we know that Ooooh is going to be big. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. We also hope to win Startup Fictional Business of the Year this Year. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. - [Centered Slides Full-Width](https://capsida.com/portfolio/centered-slides-full-width/) - We are excited to launch our new company and product Ooooh. After being featured in too many magazines to mention and having created an online stir, we know that Ooooh is going to be big. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. We also hope to win Startup Fictional Business of the Year this Year. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. - [Sidebar Page Builder](https://capsida.com/portfolio/sidebar-page-builder/) - We are excited to launch our new company and product Ooooh. After being featured in too many magazines to mention and having created an online stir, we know that Ooooh is going to be big. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. - [Sidebar Stack Full-Width](https://capsida.com/portfolio/sidebar-stack-full-width/) - We are excited to launch our new company and product Ooooh. After being featured in too many magazines to mention and having created an online stir, we know that Ooooh is going to be big. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. We also hope to win Startup Fictional Business of the Year this Year. - [Centered Dynamic Contents](https://capsida.com/portfolio/centered-dynamic-contents/) - Dynamic Contents play an essential role in creating layout templates. The Dynamic Contents features let you automatically insert content from WordPress in your designs. With the Dynamic Contents options, it's possible to create personalized and dynamic layouts by populating data from various sources. - [Sidebar Gallery](https://capsida.com/portfolio/sidebar-gallery/) - We are excited to launch our new company and product Ooooh. After being featured in too many magazines to mention and having created an online stir, we know that Ooooh is going to be big. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. We also hope to win Startup Fictional Business of the Year this Year. - [Centered Stack Full-Width](https://capsida.com/portfolio/centered-stack-full-width/) - We are excited to launch our new company and product Ooooh. After being featured in too many magazines to mention and having created an online stir, we know that Ooooh is going to be big. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. We also hope to win Startup Fictional Business of the Year this Year. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. - [Centered Page Builder](https://capsida.com/portfolio/centered-page-builder/) - We are excited to launch our new company and product Ooooh. After being featured in too many magazines to mention and having created an online stir, we know that Ooooh is going to be big. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. We also hope to win Startup Fictional Business of the Year this Year. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. - [Sidebar Slides](https://capsida.com/portfolio/sidebar-slides/) - We are excited to launch our new company and product Ooooh. After being featured in too many magazines to mention and having created an online stir, we know that Ooooh is going to be big. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. We also hope to win Startup Fictional Business of the Year this Year. - [Centered Gallery](https://capsida.com/portfolio/centered-gallery/) - We are excited to launch our new company and product Ooooh. After being featured in too many magazines to mention and having created an online stir, we know that Ooooh is going to be big. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. We also hope to win Startup Fictional Business of the Year this Year. You may have seen us in the Dinosaurs’ Den where we were we told that we didn’t need them because we were already doing it so well ourselves, so that’s what we have continued to do. ## Categories - [News](https://capsida.com/category/news/) - [community-letter](https://capsida.com/category/community-letter/) - [Company Updates](https://capsida.com/category/company-updates/) ## Portfolio Categories - [Web](https://capsida.com/portfolio_cat/web/) - This is a custom category page for Web. - [Adv](https://capsida.com/portfolio_cat/adv/) - This is a custom category page for Adv. - [Branding](https://capsida.com/portfolio_cat/branding/) - This is a custom category page for Branding. - [Design](https://capsida.com/portfolio_cat/design/) - This is a custom category page for Design. - [Photo](https://capsida.com/portfolio_cat/photo/) - This is a custom category page for Photo. ## Categories - [Creative](https://capsida.com/page_category/creative/) - This is a custom category page for Creative.